Clopidogrel Resistance: Case reports of CYP2C19 gene variants in suspected coronary stent thrombosis

Heart Lung and Circulation

Volumn 20, Issue 10, 2011, Pages 657-658

  Dick, Ronald J ^a   Dear, Anthony E ^b,c   Byron, Keith A ^b  

^a EPWORTH HOSPITAL   (Australia)

^b Molecular Pathology   (Australia)

^c MONASH UNIVERSITY   (Australia)

Author keywords

Clopidogrel; CYP2C19 gene; Stent; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; CYTOCHROME P450 2C19; DRUG METABOLITE; PRASUGREL;

ACUTE HEART INFARCTION; ADULT; ANGINA PECTORIS; ARTICLE; BARE METAL STENT; CASE REPORT; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY OBSTRUCTION; CORONARY STENT; DRUG CHOICE; DRUG ELUTING STENT; DRUG METABOLISM; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GENETIC VARIABILITY; GENOTYPE; HUMAN; MALE; PATIENT REFERRAL; PERCUTANEOUS CORONARY INTERVENTION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; STENT THROMBOSIS; THORAX PAIN; THROMBOCYTE AGGREGATION INHIBITION; TRANSLUMINAL CORONARY ANGIOPLASTY;

ARYL HYDROCARBON HYDROXYLASES; CORONARY STENOSIS; DRUG RESISTANCE; FEMALE; GENOTYPE; HUMANS; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; POLYMORPHISM, SINGLE NUCLEOTIDE; STENTS; THROMBOSIS; TICLOPIDINE;

EID: 80052962013     PISSN: 14439506     EISSN: 14442892     Source Type: Journal    
DOI: 10.1016/j.hlc.2010.06.1054     Document Type: Article

References (11)

1. Yusuf S., Zhao F., Mehta S.R., Chrolavicius S., Tognoni G., Fox K.K. Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Eng J Med 2001, 345:494-502.
2. Angiolillo D.J., Fernandez-Ortiz A., Bernardo E., Alfonso F., Macaya C., Bass T.A. Costa MAVariability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol 2007, 49:1505-1516.
3. Ferreiro J.L., Angiolillo D.J. Clopidogrel response variability: current status and future directions. Throm Haemost 2009, 102:7-14.
4. Hulot J.S., Bura A., Villard E., Azizi M., Remones V., Goyenvalle C., Aiach M., Lechat P., Gaussem P. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 2006, 108:2244-2247.
5. Collet J.P., Hulot J.S., Pena A., Villard E., Esteve J.B., Silvain J., Payot L., Brugier D., Cayla G., Beygui F., Bensimon G., Funck-Brentano C., Montalescot G. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 2009, 373:309-317.
6. Mega J.L., Close S.L., Wiviott S.D., Shen L., Hockett R.D., Brandt J.T., Walker J.R., Antman E.M., Macias W., Braunwald E., Sabatine M.S. Cytochrome p-450 polymorphisms and response to clopidogrel. N Eng J Med 2009, 360:354-362.
7. Simon T., Verstuyft C., Mary-Krause M., Quteineh L., Drouet E., Méneveau N., Steg P.G., Ferrières J., Danchin N., Becquemont L French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Investigators. Genetic determinants of response to clopidogrel and cardiovascular events. N Eng J Med 2009, 360:363-375.
8. Sibbing D., Stegherr J., Latz W., Koch W., Mehilli J., Dörrler K., Morath T., Schömig A., Kastrati A., von Beckerath N. Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. Eur Heart J 2009, 30:916-922.
9. Dear AE, Deam D, Tanti TT, Byron KB. In Proceedings Haematology Society of Australia Annual Scientific Meeting. 2009. October.
10. Bonello L., Palot-Bonello N., Armero S., Camoin-Jau L., Paganelli F. Impact of loading dose adjustment on platelet reactivity in homozygotes of the 2C19 2 loss of function polymorphism. Int J Cardiol 2009, (August 25). [Epub ahead of print].
11. Wilson W., Gurvitch R., Ajani A.E. Prasugrel: a novel platelet ADP P2Y receptor antagonist. Cardiovasc Ther 2009, 27:194-198.